RxDoctor Payments Data

Bruce Fisher, MD

Cardiovascular Disease · Louisville, KYNPI 1508854266

Payments from drug & device makers

$2,500in general payments, 2019–2025

Across 146 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$596
  • Novartis$367
  • Boston Scientific$261
  • E.r. Squibb & Sons, L.L.C.$190
  • Johnson & Johnson$181
  • AstraZeneca$133
  • plus $773 from 17 others

What the payments were for

  • Speaking & faculty fees$1255%
  • Food & beverage$2,25090%
  • Education$1265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,500 in reported general payments places this provider in the 45th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$165,798
Medicare patients
740
Services billed
1,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab356$274,764
EliquisApixaban279$268,301
EntrestoSacubitril/Valsartan114$125,595
XareltoRivaroxaban96$85,815
FarxigaDapagliflozin Propanediol37$34,117
BrilintaTicagrelor36$29,800
Praluent PenAlirocumab35$20,142
Cardizem CdDiltiazem Hcl12$17,035
JardianceEmpagliflozin12$12,889
NexletolBempedoic Acid23$11,330
Metoprolol Succinate759$8,185
NexlizetBempedoic Acid/Ezetimibe11$6,642
Ezetimibe288$6,153
Nebivolol Hcl67$5,326
Atorvastatin Calcium660$4,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$268,301279 claims
NovartisEntresto$367$125,595114 claims
Johnson & JohnsonXarelto$181$85,81596 claims
AstraZenecaFarxiga, Brilinta$133$63,91673 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$41$17,97234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →